Pfizer lung cancer pill rejected by NICE

People walk past the Pfizer Inc. headquarters in New YorkLONDON (Reuters) – Pfizer's new lung cancer pill Xalkori is too expensive to be worth using on Britain's state health service, the country's health cost watchdog said on Wednesday. The National Institute for Health and Clinical Excellence (NICE) said the drug, which works by blocking enzymes that can stimulate tumour growth, could not be considered a cost-effective use of National Health Service resources. The agency's draft guidance on the drug – which costs 4,689 pounds for a 30-day supply – is now open for consultation. …

European Union in "denial" that sick economy costs lives, health experts say

By Ben Hirschler LONDON (Reuters) – Europe’s financial crisis is costing lives, with suicides and infectious diseases on the rise, yet politicians are not addressing the problem, health experts said on Wednesday. Deep budget cuts and growing unemployment are tipping more people into depression, and falling incomes mean fewer people can see their doctors or afford to buy medicines. …

Some healthcare costs may rise when "Obamacare" implemented: official

By Jeff Mason and David Morgan WASHINGTON (Reuters) – President Barack Obama’s top healthcare adviser acknowledged on Tuesday that costs could rise in the individual health insurance market, particularly for men and younger people, because of the landmark 2010 healthcare restructuring due to take effect next year. U.S. Health and Human Services Secretary Kathleen Sebelius said definitive data on costs will not be available until later this year when private health plans become authorized to sell federally subsidized coverage on new state-based online marketplaces, known as exchanges. …

Analysis: History casts doubt on bold Japan economic reform

Japan's PM Abe gestures as he delivers his speech during the ruling LDP annual convention in TokyoBy Linda Sieg TOKYO (Reuters) – If past is precedent, optimists hoping Japanese Prime Minister Shinzo Abe will defy vested interests to take bold action to open the country to more competition as a way to spur growth could well be in for disappointment. Japan's list of reports urging reforms date back almost three decades and have rarely led to the bold action that critics say is needed to dig the economy out of stagnation. …

1 10 11 12 13 14 83